Article
A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).
Cancer medicine - 1 Dec 2017
Ishiguro Hiroshi, Saji Shigehira, Nomura Shogo, Tanaka Sunao, Ueno Takayuki, Onoue Masahide, Iwata Hiroji, Yamanaka Takeharu, Sasaki Yasutsuna, Toi Masakazu
Abstract excerpt
S-1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)-negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and homozygous for UGT1A1 *6 or *28 or compound heterozygous (*6/*28) were excluded. A dose-escalation design was chosen...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.